Epoetin Alfa Production Cost Reports

The report provides a detailed analysis essential for establishing an Epoetin Alfa production plant. It encompasses all critical aspects necessary for Epoetin Alfa production, including the cost of Epoetin Alfa production, Epoetin Alfa plant cost, Epoetin Alfa production costs, and the overall Epoetin Alfa production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Epoetin Alfa production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Epoetin alfa is a recombinant therapeutic protein that helps the body produce red blood cells. It is widely used for the treatment of anaemia, especially in patients with chronic kidney disease, cancer patients receiving chemotherapy, and individuals undergoing certain surgical procedures. The drug works by stimulating the production of red blood cells in the bone marrow, which helps improve oxygen delivery in the body. It is commonly given to patients undergoing dialysis or chemotherapy to help maintain healthy haemoglobin levels and reduce the need for blood transfusions. It often plays an important role in managing anaemia associated with long-term illnesses. Additionally, epoetin alfa is also widely used in hospitals and healthcare facilities as part of supportive care to improve the quality of life of patients during treatment.

The demand for Epoetin Alfa is primarily driven by its application as a man-made form of a protein that stimulates red blood cell production, which boosts its market expansion. Its application as a synthetic hormone medication in the treatment of anaemia in various medical conditions significantly contributes to its demand in the medical and healthcare sectors. Its application in the treatment of anaemia caused by chronic kidney disease, cancer treatments, or certain medications that reduce red blood cell levels also fuels its demand in the medical sector.

Its usage as a drug to reduce the need for blood transfusions in patients with low haemoglobin levels also promotes its demand in the dialysis and cancer care sectors. Advancements in biosimilar development, consistent product quality, supplier credibility, and compliance with safety standards also play a major role in shaping its overall market. Additionally, industrial Epoetin alfa procurement is influenced by several factors, including the availability and cost of biologic raw materials, regulatory approvals, production capacity, and cold chain logistics.

Raw Material for Epoetin Alfa Production

According to the Epoetin Alfa production plant project report, the major raw materials for Epoetin Alfa production includes Chinese hamster ovary cells.

Production Process of Epoetin Alfa

The extensive Epoetin Alfa production cost report consists of the following industrial production process:

1. Production via Recombinant DNA Technology: The production process of Epoetin alfa begins with the insertion of the human erythropoietin gene into Chinese hamster ovary cells. Then, these mammalian cells are cultured to produce the recombinant human erythropoietin protein, known as rEPO. During production, the cells glycosylate the protein in a manner similar to human cells, ensuring proper structure and function. The complete process leads to the formation of Epoetin Alfa as the final product.

Epoetin alfa is a recombinant form of human erythropoietin, which is a glycoprotein hormone that promotes red blood cell production. It appears as a sterile, colourless to pale yellow, clear solution in single-use vials or prefilled syringes for parenteral administration. The molecular formula of the compound varies due to glycosylation, but one reported approximation is C815H1317N233O241S5 due to its complex glycosylated structure, with a molar mass of approximately 30,400 Da. The compound is odourless and has a density of around 1.02–1.05 g/cm³ as an aqueous formulation. The melting point of the compound is around 53 degree Celsius. It is chemically stable at refrigerated conditions (2–8 degree Celsius) in phosphate buffer at pH 6.9. It is soluble in aqueous media but sensitive to shaking, heat, or light. Handling the compound requires cold chain storage and precautions against immunogenicity, as improper use can cause thrombotic events, hypertension, or pure red cell aplasia.